How to set up a psychedelic study: Unique considerations for research involving human participants

Marcus J. Glennon, Catherine I. V. Bird, Prateek Yadav, Patrick Kleine, Shayam Suseelan, Christina Boman-Markaki, Vasileia Kotoula, Matt Butler, Robert Leech, Leor Roseman, David Erritzoe, Deepak P. Srivastava, Celia Morgan, Christopher Timmermann, Greg Cooper, Jeremy I. Skipper, James Rucker, Sunjeev K. Kamboj, Mitul A. Mehta, Ravi K. Das, Anjali Bhat

View at source ↗PDF ↗Article3 citations

Abstract

Setting up a psychedelic study can be a long, arduous, and kafkaesque process. This rapidly-developing field poses several unique challenges for researchers, necessitating a range of considerations that have not yet been standardised. Many of the complexities inherent to psychedelic research also challenge existing assumptions around, for example, approaches to psychiatric prescribing, the conceptual framing of the placebo effect, and definitions of selfhood. This review paper brings together several of the major psychedelic research teams across the United Kingdom to formalise these unique considerations, identify continuing areas of debate, and provide a practical, experience-based guide, with recommendations for policymakers and future researchers intending to set up a psychedelic research study or clinical trial. We approach this such that the paper can either be read end to end, or treated as a manual: readers can dip into relevant sections as needed.

Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.

Record

Archive ID
arxiv:2503.22808
Published
Mar 28, 2025
Updated
Apr 18, 2025
Venue
Neuroscience & Biobehavioral Reviews
DOI
10.1016/j.neubiorev.2026.106657
arXiv
2503.22808
Categories
q-bio.NC
Provenance
arxiv

Topics